Tim Surgenor

Tim Surgenor co-founded Red Sky Partners in 2009 and is its managing partner. He is a creative biotechnology industry professional who has held executive leadership positions in companies focused on commercializing pioneering biotechnology products. He is skilled in public and private company corporate governance, strategy, finance, business development and all functional aspects of product development.

Since founding Red Sky in 2009, Tim has been a trusted advisor to biotech CEOs and board members. His recent accomplishments include closing a European licensing deal for a late-stage cell therapy, leading the virtual management team for Merrimack Pharmaceuticals to a significant dividend for investors, and spearheading the partnering process that resulted in protein engineering deal for Kymera Therapeutics with Sanofi. He has also served as an interim CBO for multiple public and private companies, maintaining long-term advisory relationships with clients at various stages of development.

Tim has extensive general management experience in biotechnology companies, with executive roles including public company CEO, CFO, board member and audit committee chair. Previously, Tim was Executive Vice President of Haemonetics, where he ran business development and global marketing and led numerous technology and company acquisitions. As President of Genzyme’s Tissue Repair Division, he led the worldwide launch of several cellular therapy products and was a member of the Genzyme Corporation’s investor relations and financing team. Tim has also served as CEO of Cyberkinetics and CFO of BioSurface Technology.

Tim has an MBA from the Harvard Graduate School of Business Administration a BA in Biochemistry from Williams College.